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Spinal cord injury (SCI) is a debilitating clinical condition, characterized by a complex of neurological dys-
functions. Neural stem cells from the subventricular zone of the forebrain have been considered a potential tool 
for cell replacement therapies. We recently isolated a subclass of neural progenitors from the cadaver of mouse 
donors. These cells, named postmortem neural precursor cells (PM-NPCs), express both erythropoietin (EPO) 
and its receptor. Their EPO-dependent differentiation abilities produce a significantly higher percentage of neu-
rons than regular NSCs. The cholinergic yield is also higher. The aim of the present study was to evaluate the 
potential repair properties of PM-NPCs in a mouse model of traumatic SCI. Labeled PM-NPCs were adminis-
tered intravenously; then the functional recovery and the fate of transplanted cells were studied. Animals trans-
planted with PM-NPCs showed a remarkable improved recovery of hindlimb function that was evaluated up to 
90 days after lesion. This was accompanied by reduced myelin loss, counteraction of the invasion of the lesion 
site by the inflammatory cells, and an attenuation of secondary degeneration. PM-NPCs migrate mostly at the 
injury site, where they survive at a significantly higher extent than classical NSCs. These cells accumulate at 
the edges of the lesion, where a reach neuropile is formed by MAP2- and b-tubulin III-positive transplanted 
cells that are also mostly labeled by anti-ChAT antibodies.
Key words: Spinal cord injury (SCI); Neural stem cells; Transplantation; Regenerative medicine; Animal 
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INTRODUCTION
Spinal cord injury (SCI) is most commonly caused 
by high-energy trauma, and the majority of patients are 
10–40 years old. SCI results in enormous personal suffer-
ing and substantial costs to society (10,33). There is cur-
rently no curative therapy, and the care in the acute phase 
is often limited to high-dose corticosteroid treatment, 
and surgical stabilization and decompression to possibly 
attenuate further damage (10,11). In addition to axonal 
transection, the traumatic injury and the activation of sec-
ondary mechanisms of degeneration cause demyelination 
and death of multiple cell types (12,32). The degree of 
recovery of function can be correlated to the extent of 
spared white matter at the injury site (43). A large num-
ber of studies have evaluated the effects of transplanting 
a variety of stem cells or stem cell-derived cells in SCI 
models, and remarkably, many studies using different 
strategies have indicated beneficial effects to a certain 
degree (30). Transplanted cells can improve the recov-
ery of function either by replacing partially the lost cells 
or supplying a favorable environment that attenuates the 
effects of secondary degeneration. Therefore, they could 
enhance the amount of spared tissue at the injury site 
(i.e., transplanted stem cells can survive in such an unfa-
vorable environment). We had previously reported that 
intravenously (IV) administered adult neural stem cells 
(NSCs), isolated from the subventricular zone (SVZ), 
accumulate at the site of injury and improve the early rate 
of hindlimb functional recovery. Their liability, however, 
lasts just about 12–20 days; then NSCs are phagocytized 
by macrophages, and the recovery process does not prog-
ress further (4). A similar fate had also been observed 
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with embryonic stem cells (ESCs), although their anti-
inflammatory action, accompanied by a good degree of 
myelin preservation, promoted an early improvement of 
hindlimb functional recovery (5). In view of such results 
and aiming at the isolation of adult NSCs capable of sur-
viving in a highly unfavorable environment, we isolated 
adult NSCs from the SVZ several hours after death of 
the mouse donor (23). This procedure provides a popu-
lation of NSCs, named postmortem neural precursor 
cells (PM-NPCs), which differentiate preferentially into 
neurons in vitro with a significant percentage of cells of 
cholinergic nature. Such a process is dependent on the 
autocrine erythropoietin (EPO) release and is prevented 
by exposure to EPO and EPOR antibodies (23). Here we 
report that IV-administered mouse PM-NPCs migrate to 
the spinal cord lesion site, differentiate mostly into cho-
linergic neuron-like cells, and form a reach neuropile. 
These differentiation events are preceded by the counter-
action of secondary degeneration that is accompanied by 
the promotion of a stable recovery of hindlimb function.
MATERIALS AND METHODS
Animal Care
For this study we used 71 adult CD1 male mice 25–30 g 
in weight (Charles River, Calco, Italy). All of the procedures 
were approved by the Review Committee of the University 
of Milan and met the Italian Guidelines for Laboratory 
Animals, which conform to the European Communities 
Directive of November 1986 (86/609/EEC). The animals 
were kept for at least 3 days before the experiments in stan-
dard conditions (22 ± 2°C, 65% humidity, and artificial light 
between 8:00 a.m. and 8:00 p.m.).
Postmortem-Neural Precursor Cell Derivation, 
Differentiation, and Labeling
PM-NPCs were obtained from 6-week-old CD-1 
albino mice; their isolation, growth, and characterization 
were performed following methods described by Gritti et 
al. (17). Briefly, cells were isolated from the SVZ 6 h after 
sacrifice by cervical dislocation. Brains were removed, and 
tissues containing the SVZ region were dissected, trans-
ferred to Earl’s balanced salt solution (Life Technologies, 
Monza, Italy) containing 1 mg/ml papain (27 U/mg; 
Sigma-Aldrich, Milan, Italy), 0.2 mg/ml cysteine (Sigma-
Aldrich), and 0.2 mg/ml EDTA (Sigma-Aldrich). Tissue 
was incubated for 45 min at 37°C on a rocking platform. 
Tissues were then transferred to DMEM-F12 medium 
(Euroclone, Pero, Milan, Italy) and mechanically dis-
sociated with a Pasteur pipette. Cells were collected by 
centrifugation (200 × g, 10 min, room temperature) and 
resuspended in DMEM-F12 medium (Euroclone) contain-
ing 2 mm l- glutamine (Euroclone), 0.6% glucose (Sigma-
Aldrich), 9.6 mg/ml putrescine (Sigma-Aldrich), 6.3 ng/
ml progesterone (Sigma-Aldrich), 5.2 ng/ml sodium 
selenite (Sigma-Aldrich), 0.025 mg/ml insulin (Sigma-
Aldrich), 0.1 mg/ml transferrin (Sigma-Aldrich), 2 µg/ml 
heparin (sodium salt, grade II; Sigma-Aldrich), basic 
fibroblast growth factor (bFGF; human recombinant, 
10 ng/ml; Life Technologies), and epidermal growth factor 
(human recombinant, 20 ng/ml; Life Technologies) (5,17). 
PM-NPC precursors were maintained in culture in the 
above-cited medium (5,17). Differentiation of PM-NPCs 
was performed by plating the dissociated stem cells at a 
density of 40,000 cells/cm2 in the presence of adhesion 
molecules (Matrigel™; BD Biosciences, Buccinasco, 
MI, Italy) and bFGF (10 ng/ml) for 48 h. Cells were then 
exposed to the same medium without bFGF and the addi-
tion of fetal bovine serum (2% v/v; Euroclone) for the 
following 5 days as previously described (17,23). Then, 
the extent of differentiation was determined by immu-
nocytochemical staining (23). PM-NPCs were labeled 
with PKH26 (Sigma-Aldrich) just before transplantation 
according to the manufacturer’s instructions. Briefly, cells 
were collected and washed thrice using HBSS (Life 
Technologies) in a 10-ml conical vial. After the last wash, 
the supernatant was aspirated, leaving in the tube no more 
than 25 µl of supernatant. A 2× cell suspension was pre-
pared by adding 1 ml of Diluent C to the cell pellet fol-
lowed by gentle pipetting. Immediately before staining, a 
2× dye solution (4 × 10–6 M) in Diluent C was prepared by 
adding 4 ml of the PKH26 ethanol dye solution to 1 ml of 
Diluent C. The 1 ml of 2× cell suspension was added to 
1 ml of 2× dye solution and incubated for 3 min at room 
temperature (final cell density was 1.2 × 107 cells/ml and 
2 × 10–6 M PKH26). The staining was stopped by adding an 
equal volume (2 ml) of 1% bovine serum albumin (Sigma-
Aldrich) solution in HBSS and incubated for 1 min. Cells 
were washed twice with HBSS to ensure removal of 
unbound dye. After the last centrifugation, the cell pellet 
was resuspended in a sterile saline solution. The final cell 
concentration was 3.3 × 105 cells/50 µl (15,20,41). PKH26 
is an nontoxic cell dye characterized by long aliphatic tails 
(PKH26) that allow the dye incorporation in lipid regions 
of the cell membrane (20,41).
Green Fluorescent Protein (GFP) PM-NPCs
PM-NPCs were obtained from 2-month-old C57 
black male mice carrying the transgene for GFP under 
the control of ubiquitin promoter C [C57BL/6-Tg(UBC-
GFP)30Scha/J; The Jackson Laboratories, Bar Harbor, 
ME, USA]. These precursors were characterized in vitro 
for neurosphere formation and differentiation capabili-
ties, which resulted comparable to those of the PM-NPCs 
obtained from albino CD1 mice (5,17,23).
Dead Cell Administration
PM-NPCs (1 × 106 cells) were treated with 1 ml of 4% 
paraformaldehyde (Sigma-Aldrich) for 10 min at room 
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temperature, 10 ml of PBS was added, cells were spun 
down at 123 ×  g, and suspended in PBS. This washing 
step was performed twice, and finally, the ready-to-use 
dead PM-NPCs were suspended at the final concentration 
of 3.3 × 105 cells/50 µl in saline solution.
Cell Quantification at the Lesion Site
Cells were considered PKH26 positive when fluores-
cence was visible by confocal microscope (Leica TSC2; 
Leica Microsystems, Heidelberg, Germany) and if the 
spots had an emission wave length of 567 nm, which 
corresponds to the emission of PKH26. We used sec-
tions obtained from animals transplanted with unlabeled 
PM-NPCs as a control. The counting of the cells was 
performed by assessing the PKH26-positive cells in the 
transversal sections in a region 4 mm from the center of 
the lesion site. The lesion epicenter was defined in cross-
sections as the region with the minimum tissue sparing. 
The PKH26-positive cells present in a group of three con-
secutive sections (10 µm thick) were averaged, and the 
count was repeated every 400 µm. The total number of 
labeled cells was obtained integrating the curve obtained 
calculating the average of each section across a 4-mm 
span from the epicenter of the lesion (8).
Spinal Cord Injury, Experimental Groups,  
and Cell Administration
The traumatic SCI was performed using a commer-
cially available Infinite Horizon (Precision Systems and 
Instrumentation, LLC, Lexington, KY, USA) SCI device 
(18,31) at the T8 level. Surgery on the animals was per-
formed with minor modifications of the method described 
elsewhere (18). Briefly, animals were anesthetized with 
2.5% isoflurane in oxygen (1 L/min; Farmagricola, San 
Donato, Milan, Italy) for 5 min before surgery. A dorsal 
vertical incision was made through the skin from T7 to 
T12. The superficial fat pad was removed, and T7 and T10 
bilateral paravertebral muscles were cut. Laminectomy was 
performed, and the spinal cord was exposed. The impac-
tor tip was then positioned just above the cord following 
the manufacturer’s instructions. A force of 70 Kdyne was 
applied for 1 s to the spinal cord. After the contusion, the 
muscles were sutured, and the skin closed by means of 
clips (2Biological Instruments, Besozzo, Varese, Italy). 
Experimental animals were divided into four groups: 
1) laminectomy mice (n = 11), 2) lesioned mice treated 
by IV route with phosphate-buffered saline (PBS, n = 22), 
3) lesioned mice transplanted by IV route with PM-NPCs 
(n = 22), and 4) lesioned mice transplanted by IV route 
with dead PM-NPCs (n = 12). IV administration was per-
formed by injections in the tail vein. PM-NPCs, PBS, or 
dead PM-NPCs were administered after spinal cord lesion. 
The first treatment was a slow IV injection of 50 µl in the 
tail vein performed within 30 min after injury, followed by 
a second injection 6 h later, and a third one 18 h after the 
lesion. Each cellular administration consisted of 3.3 × 105 
cells in PBS for a total of 1 × 106 cells. The choice of a 
time limit of 18 h after SCI for administering PM-NPCs 
was determined by the optimal permeability of the blood–
brain barrier at this time (42). PM-NPCs between the fifth 
and the ninth passage in culture were used for these experi-
ments. The cultures were tested for proliferation and dif-
ferentiation ability before being transplanted (23).
Behavioral Tests and Hindlimb Function
All outcome measures were assessed in a blinded 
 fashion. Neurological function was evaluated first 24 h 
after injury and then twice a week for the first 4 weeks. The 
methods utilized are well known in the field of behavioral 
evaluation of recovery of function after SCI. Locomotor 
function and hindlimb recovery after contusion were 
evaluated with the open field test according to the Basso 
mouse rating scale (3). For behavioral experiments we 
used five animals in the laminectomy group and at least 
12 animals for the other groups. Allodynia-like responses 
in the unaffected forepaw were assessed by means of stan-
dard hotplate test and cold stimulation. For hotplate test-
ing, mice were placed on a hotplate, and the latency to 
licking was measured. Nonresponders were removed after 
60 s. The response to cold was tested by the application of 
ethyl chloride spray (Gebauer Company, Cleveland, OH, 
USA) to the palm surface. The response was rated 1 (no 
response), 2 (brief withdrawal with licking), and 3 (vocal-
ization, withdrawal with licking, and aversion) (19).
Fluorescence Imaging
An IVIS Lumina (Caliper LifeSciences Perkin Elmer, 
Monza, Italy) CCD camera was used to assess the fluo-
rescent signal in organs collected from lesioned mice 
intravenously injected with PKH26-labeled cells and 
control mice injected with saline. Briefly, 48 h after injec-
tion, three animals per group were sacrificed, and organs 
(spinal cord, bowel, kidney, liver, spleen, and lungs) were 
collected. Fluorescence imaging was performed by using 
the DsRed and DsRed background excitation and emis-
sion passband filters (DsRed: excitation 500–550 nm, 
emission 575–650 nm; DsRed-background: excitation: 
460–490 nm, emission: 575–650 nm). Image analyses 
were performed with Living Image® software (Caliper 
LifeSciences; Perkin Elmer) for background subtraction.
In Vivo MRI
MRI was performed using a 7T MR scanner (Bruker, 
Milan, Italy). Anesthetized animals (isofluorane gas 
anesthesia; Farmagricola) were positioned supine on the 
animal bed and inserted in the radiofrequency coil (diam-
eter = 38 mm) inside the magnet. Scout transverse images 
were acquired for correct positioning of the region of 
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interest. Different MR sequences were tried in order to 
optimize spinal cord visualization and signal contrast:
Spin echo (MSME) sequence, (matrix 256 × 128; TR/•	
TE: 1,200/12 ms; two averages; acquisition time: 5¢7²; 
fat suppression used) 
Gradient echo (FLASH) sequence (matrix 256 × 128; •	
TR/TE: 1,200/10 ms; two averages; acquisition time: 
5¢7²); not shown
Fast-spin echo (RARE) sequence (matrix 256 × 128; •	
TR/TE: 2,000/56 ms; four averages; acquisition time: 
4¢16²).
All animals (n = 4 for each group) were acquired in 
transverse (five slices of 0.7 mm thickness; FOV 4 × 4 
and spatial resolution of 156 µm) and axial orientations 
(12 slices of 0.7 mm thickness; FOV 3 × 3 and spatial 
resolution of 117 µm) 10 months after lesion.
Tissue Collection and Processing, Histology, 
and Immunohistochemistry
At the end of the experimental period, animals were 
anesthetized by IP injection of cloralium hydrate (Sigma-
Aldrich) 4% in distilled water and perfused with 4% 
paraformaldehyde in phosphate buffer 0.1 M pH 7.4 
by transcardial perfusion. Spinal cords were postfixed 
overnight in the same fixative, cryoprotected with 30% 
sucrose (Sigma-Aldrich), quickly frozen, stored at −80°C, 
and sectioned by means of a cryostat (Leica). Every 20th 
section was stained with thionin (Sigma-Aldrich). Cross-
sections containing the lesion epicenter and the complete 
T8 segment cavitations were analyzed by computer-
assisted image analysis. The percent of lesion was cal-
culated as the area of the injured tissue divided by the 
area of the total cross-section at the level of the injury. 
Coronal sections (15 µm) were also collected onto glass 
slides and processed for immunocytochemistry. Sections 
were rinsed with PBS (Euroclone), treated with blocking 
solution (Life-Technologies), and incubated with primary 
antibodies overnight at 4°C. After treatment with pri-
mary antibodies, the sections were washed with PBS and 
incubated with appropriate secondary antibodies (Alexa 
Fluor® 546 or/and Alexa Fluor® 488, Molecular Probes®, 
Life Technologies) for 2 h at room temperature. Sections 
were washed in PBS, nuclei were stained with DAPI 
(1 mg/ml final concentration, 10 min at room temperature; 
Sigma-Aldrich), mounted using the FluorSave Reagent 
(Calbiochem, Merck Chemical, Darmstadt, Germany), 
and analyzed by confocal microscopy. In control deter-
minations, primary antibodies were omitted and replaced 
with equivalent concentrations of unrelated IgG of the 
same subclass. The following primary antibodies were 
used: microtubule-associated protein 2 (MAP2; 1:300; 
Millipore, Vimodrone, Milan, Italy), glial fibrillary acidic 
protein (GFAP; 1:400; Covance, Rome, Italy), b-tubulin 
III (1:150; Covance), choline acetyltransferase (ChAT; 
1:1,000; Millipore), and immunological response (ED1) 
rat anti-mouse macrophages/monocytes (1:25; Millipore). 
For immunofluorescence, the following secondary anti-
bodies were used: 488 goat anti-mouse IgG (1:200; 
Alexa), 488 donkey anti-rabbit IgG (1:200; Alexa), 546 
goat anti-rabbit IgG (1:200; Alexa), and 546 goat anti-
chicken IgG (1:200; Alexa).
Assessment of Myelin Preservation
In order to perform a homogeneous analysis, the staining 
was carried out on sections of nonlesioned, lesion + saline, 
and lesion + cells animals placed on the same coverslip. 
Myelin preservation was evaluated comparing the levels 
of myelin in the ventral white matter at 0.4 mm (rostral and 
caudal) laterally from the lesion epicenter in healthy, saline, 
and cell-treated animals. The choice of the ventral white 
matter was based on the knowledge that the reticular spi-
nal pathway descends mostly in the ipsilateral dorso- and 
ventrolateral funiculi and is directly involved in the regula-
tion of the movement of the mouse foot (40). We previ-
ously reported that the quantification of the spared ventral 
myelin evaluated in a semithin section gave comparable 
results when fluoromyelin was used (FluoroMyelin Green, 
Molecular Probes; Invitrogen, Eugene, OR, USA) (40). The 
confocal microscope images for the laminectomy, saline, 
and cell-treated mice were obtained using the same inten-
sity, pinhole, wavelength, and thickness of the acquisition. 
As reference, we used sections close to the ones analyzed 
and not treated with fluoromyelin. Briefly, the procedure of 
the staining was carried out by incubating the cryosections 
with fluoromyelin diluted 1:300 in PBS for 20 min; slides 
were then washed three times for 10 min each with PBS and 
mounted with FluorSave (Merck, Darmstadt, Germany), 
and qualitatively and quantitatively analyzed by confocal 
microscopy (Leica TSC2; Leica Microsystems).
Estimate of the Macrophage Number  
at the Site of the Lesion
ED-1-positive cells were counted in transversal sections 
made at the lesion epicenter (1 mm extension) and 0.4 mm 
rostral. As a negative reference, we used a consecutive sec-
tion that was stained by omitting primary antibody anti-rat 
macrophages/monocytes and replacing it with equivalent 
concentrations of unrelated IgG of the same subclass. The 
zero level was adjusted on this reference and used for all 
the further analysis (we used a new zero reference for each 
new staining). The ED-1-positive cells present in a group 
of three consecutive sections (10 µm thick) were averaged, 
and we repeated this count each 100 µm. The total number 
of ED-1-positive cells was obtained integrating the aver-
age within volume analyzed, that is, the 1 mm around the 
epicenter of the lesion (8).
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Estimate of Neutrophil Tissue Infiltration
Spinal cords, dissected 48 h after lesioning, were placed 
overnight in 4% formaldehyde, 50 mM phosphate buffer 
solution, pH 7.4, and then paraffin embedded. Sections 
of 5 mm thickness were cut through the epicenter (1 mm) 
and stained with Harris hematoxylin and eosin (Sigma-
Aldrich, Milan, Italy). Neutrophils were identified by 
means of the Leder technique that employs naphthol AS-D 
chloroacetate (Sigma-Aldrich, Milan, Italy) dissolved in 
dimethyl sulfoxide (Sigma-Aldrich, Milan, Italy)/Triton 
X-100 (VWR, Milan, Italy) (9:1; v/v). Then pararosaniline 
hydrochloride (Sigma-Aldrich, Milan, Italy) dissolved in 
saline buffer solution was added. This was performed as 
described by Schlayer et al. (32). Red-stained polymor-
phonucleated cells were counted in four nonconsecutive 
groups, randomly chosen around the lesion site of 400× 
histological fields. Results were expressed as number of 
neutrophils per histological power field (HPF).
RNA Isolation and Real-Time PCR Analysis
Mice (n = 3 48 h postinjury group, n = 3 1 week postin-
jury group) were anesthetized (5,12,13) and sacrificed by 
decapitation. Laminectomy was performed at the T5–T12 
level. The spinal cord region corresponding to the lesion 
site was removed (we took 4 mm of tissue rostral and 4 
mm of tissue caudal to the lesion epicenter). The tissue 
was put in 1 ml of Trizol® Reagent (Invitrogen), shock 
frozen, and kept at −80°C until performing the RNA iso-
lation. Total RNA was isolated by using Trizol® Reagent 
(Invitrogen) in accordance with the manufacturer’s 
instructions. The genomic DNA was removed by DNase I 
treatments (2 U/µg of RNA) (Ambion, Austin, TX, USA). 
The synthesis of single-strand cDNA was carried out on 
1 µg of RNA, using U M-MLV Reverse Transcriptase III 
(Invitrogen) following the manufacturer’s instructions.
Real-time (RT)-PCR was performed in an MJ Opticon 
2 (Biorad, Segrate, Milan, Italy) using Brilliant SYBR 
Green qPCR Master Mix (Stratagene, La Jolla, CA, USA) 
following the manufacturer’s instructions. The house-
keeping gene glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) was used for normalization of cytokine 
expression. The relative expression of cytokine genes, 
with GAPDH as reference gene, was determined using 
the 2−DDCt method. We used this method because both tar-
get and reference genes were amplified with similar effi-
ciencies near 100%. The primer design was performed 
using the DNASTAR Lasergene program. Primers used are 
the following: GAPDH (F: cgacttcaacagcaactcccactcttcc; 
R: gctccctaggcccctcctgttattatg), brain-derived neurotrophic 
factor (BDNF) (F: cattaccttcctgcatctgttgg; R: cgtggacgtttact 
tctttcatgg), interleukin-6 (IL-6) (F: gacaaccacggccttccctac; 
R: cgttgttcatacaatcagaattgcc), nerve growth factor (NGF) 
(F: tgggcccaataaaggttttgcc; R: tgggcttcagggacagagtctcc), 
tumor necrosis factor-a (TNF-a) (F: tctatggcccagaccctcacac; 
R: cagccactccagctgctcctc), macrophage inflammatory pro-
tein 2 (MIP-2) (F: acgcccccaggaccccactg; R: ggacagcag 
cccaggctcctcc), leukemia inhibitory factor (LIF) (F: aacgt 
ggaaaagctatgtgcg; R: gcgaccatccgatacagctc).
Statistical Analysis
Data were expressed as the mean ± SEM. Multiple 
group comparisons were made by ANOVA with Tukey’s 
post hoc test. The analyses were performed using Prism 3.0 
software (GraphPad Software, Inc., La Jolla, CA, USA). 
Statistical significance was accepted for a p < 0.05.
RESULTS
PM-NPCs Improve Recovery of Hindlimb Function
The 70-Kdyne traumatic impact to the spinal cord 
caused a transient loss of ability in hindlimb function 
of saline-treated control mice, which was followed by a 
progressive gradual recovery reaching the maximum in 
2–3 weeks (3.20 ± 0.08 points of the BMS scale; n = 12) 
(Fig. 1). This corresponds to plantar placing of the paw 
with or without weight support or occasional, frequent, 
or consistent dorsal stepping, but not plantar stepping (3). 
The recovery was earlier and reached a higher recovery 
extent up to 5.14 ± 0.06 at day 28 (n = 12, corresponding to 
frequent or consistent plantar stepping without coordina-
tion or frequent or consistent plantar stepping with some 
coordination) when injured mice were treated with adult 
PM-NPCs (see Materials and Methods). The behavioral 
improvement was particularly evident between days 7 and 
14 after SCI; then it kept steadily improving thereafter 
(up to 90 days; n = 6). The application of killed PM-NPCs 
failed to improve recovery of hindlimb function, and the 
rate of recovery was comparable to that of the saline group 
(Fig. 1). No signs of allodynia-like forelimb hypersensi-
bility (19) were recorded at any time in any experimental 
group throughout the observational period of 90 days.
PM-NPC-Mediated Tissue Sparing
Spinal tissue preservation in the animals treated with 
PM-NPCs was strongly suggested by the in vivo NMR 
analysis performed in saline and cell-treated animals 10 
months after lesioning (Fig. 2). The T2-weighted RARE 
images show that in saline-treated mice the spinal cord mat-
ter become very thin at the injury site surrounded by a very 
high hyperintense signal probably due to spinal fluid filling 
the empty space left by the reduced size of the surviving 
cord. Spinal cord shrinkage at the lesion site and fluid accu-
mulation is a constant finding in all chronically lesioned 
untreated animals (Fig. 2). It was observed that the protec-
tive effect of PM-NPCs was maintained chronically, and the 
spinal cord matter was rather well preserved at site of injury 
even 10 months later. The hyperintensive signal was far less 
intense than in saline-treated animals (Fig. 2). The reduced 
tissue loss was likely due to tissue sparing. An important 
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pathway in eliciting locomotion is the reticulospinal tract 
that descends mainly in the ipsilateral dorso- and ventro-
lateral funiculi. By electrophysiological studies, its func-
tion in the coordination of rhythmic stepping movements 
was shown (2,25). In this region, myelin preservation was 
studied by means of FluoroMyelin™ staining followed by 
confocal quantitative analysis (39,40) (details in Materials 
and Methods). Myelin preservation was quantified 28 days 
after lesioning, and sections were taken at the center of the 
lesion and 0.5 and 1.9 mm caudal to the lesion site. The 
quantitative assessment was performed on spared ventral 
and lateral white matter, and it is shown in Figure 3. Only 
intact myelin was assessed, and the rubble of degenerated 
myelin was obviously not considered. The traumatic lesion 
caused almost 50% loss of myelin in close proximity of the 
lesion and about 70% more caudally. The application of 
PM-NPCs reduced such a loss in a remarkable and highly 
significant manner in all three points of evaluation (Fig. 3).
PM-NPC Homing to Site of Injury, 
Survival, and Differentiation
After 48 h from IV injection of PKH26-labeled PM- 
NPCs, mice were sacrificed, and CCD camera analysis was 
performed in the following organs: spinal cord, bowel, 
kidney, spleen, lungs, and liver. Figure 4 shows a specific 
distribution of PM-NPCs at the lesion site in the spinal cord 
bearing the highest detected fluorescence peak. A smaller 
degree of positivity was observed in the spleen (Fig. 4A). 
The comparison of spinal cords from PM-NPC- and saline- 
treated animals showed a higher and specific signal of fluo-
rescence relative to the presence of transplanted cells in 
the former and the absence of specific signal in the latter 
(Fig. 4B). We also serially sectioned seven cords of treated 
mice at 4 weeks after injury and detected PKH26- or GFP-
positive PM-NPCs by means of confocal microscopy at the 
edge of the lesion. The total number of positive cells was 
260,000 ± 45,000 per cord. This was 100-fold higher than 
surviving ESCs as reported previously and 10-fold higher 
than adult NSCs (4,5).
Figure 5 shows that the density of postinjury reactive 
GFAP-positive cellular profiles was markedly reduced in 
the proximity of the PM-NPC clusters. The quantification 
confirmed the visual impression that GFAP-positive cells 
were significantly reduced around the areas of PM-NPC 
accumulation compared to other parts of the cord located 
where the GFAP-positive cells were more numerous 
Figure 1. PM-NPCs improve recovery of hindlimb function. The open field locomotion was the test employed for the determination 
of motor function recovery. The score was determined according to the Basso Mouse Scale (BMS) (3). The experimental animals, 
tested the day prior to the injury, scored the maximum (nine points) in the BMS scale; then the BMS score fell to 0 following SCI and 
gradually recovered thereafter. The recovery of hindlimb function of lesioned mice showed a remarkable and long-lasting improve-
ment when animals were treated with live PM-NPCs. The groups were randomized, and the analysis was performed in double-blind 
fashion. Values represent mean ± SEM. We determined the statistical differences by means of ANOVA test followed by Tukey’s post-
test. ***p < 0.001; **p < 0.01 versus saline; °°°p < 0.001; °°p < 0.01 versus killed PM-NPCs.
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(Fig. 5). None of the transplanted PM-NPCs differentiated 
into GFAP-positive cells. This result was quite different 
from in vitro differentiation, where about 40–50% of the 
cells became GFAP-positive cells. Also, no transplanted 
PM-NPCs showed positivity for oligodendrocyte markers 
(data not shown).
Most engrafted PM-NPCs accumulated at the edges of 
the lesion (Figs. 6–8), where they formed clusters since the 
early days of their administration. The clusters dispersed 
along the lesion edges, and transplanted cells differentiated, 
assuming gradually the asymmetric cellular conformation 
of neurons. At 1 week after lesion and transplantation, small 
PM-NPCs were grouped along the irregular margins of the 
lesion, and almost 50% of the cells were already positive 
for MAP2 and ChAT (Figs. 6, 8). With time, the cell bod-
ies of PM-NPCS increased in size, and most cells extended 
dendritic-like processes that were immunostained by specific 
antibodies to MAP2 and b-tubulin III. This was particu-
larly evident at days 28 and 60 after lesioning (Figs. 6, 7). 
Immunohistochemical staining for ChAT revealed that most 
transplanted PM-NPCs were positive for ChAT and showed 
a marked increase in the formation of dendritic-like pro-
cesses over time (Fig. 8). Such a differentiation into cholin-
ergic neural cells in vivo confirmed the in vitro observations 
(23). The achievement of morphological complexity and 
the positivity to ChAT, MAP2, and b-tubulin III by trans-
planted PM-NPCs was not likely due to fusion with sur-
viving host spinal cord neurons (Figs. 6–8). This is evident 
from their clearly different morphology and the absence of 
two nuclei in any single labeled cell. The quantification of 
such differentiation is shown in Table 1.
PM-NPC-Mediated Chemokine and Growth 
Factor Expression in the Injured Cord
The prompt action of PM-NPCs in promoting the recov-
ery of function was suggestive of some additional effects by 
these cells beyond their cellular presence in the injured cord. 
Accordingly, we assayed the production of neurotrophic 
Figure 2. In vivo MRI 10 months after SCI. RARE sequences obtained at 10 months after injury and cell transplantation by means 
of a 7-tesla NMR (Bruker). A significantly better parenchymal preservation in PM-NPC-treated animals is shown, while there is only 
a thin residual tract in saline-treated mice that is accompanied by fluid accumulation. The images are representative for two mice, but 
similar images were obtained for at least four animals per group.
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factors and inflammatory cytokines that represent the major 
targets of pharmacological agents aimed at repair in neurode-
generative disorders. We evaluated quantitatively the mRNA 
levels of six different factors (Fig. 9): BDNF, NGF, TNF-a, 
IL-6, MIP-2, and LIF. The comparison was made between 
the animals treated with saline or PM-NPCs. As additional 
controls, we assayed the chemokines in the T9 region of 
the spinal cord of both naive uninjured and laminectomized 
animals. As expected, all of the assayed chemokines were 
increased in the cord of the lesioned animals. We observed 
Figure 3. Sparing of myelin in the injured cord. The images and the relative quantification show the protective action of PM-NPCs on 
the myelin tracts in the injured cord. After animal perfusion, spinal cords were dissected, postfixed, and coronally sectioned by means of 
a cryostat. Myelin was quantified by means of Fluoromyelin™ staining (green) performed in sections at the lesion epicenter and 0.5 mm 
and 1.9 mm caudal to the lesion site through quantitative confocal analysis of ventral and lateral white matter as indicated in the graphs. 
The confocal microscope images for the saline and PM-NPC-treated mice were obtained using the same intensity, pinhole, wavelength, 
and thickness of the acquisition. As reference, we used sections close to the ones analyzed and not treated with fluoromyelin. For the 
quantification we considered sections from at least three animals per group. Values represent the mean ± SEM. We determined the sta-
tistical differences by means of ANOVA test followed by Tukey’s posttest. °°°p < 0.001, °°p < 0.05, °p < 0.01 versus PBS; ***p < 0.001, 
**p < 0.05, *p < 0.01 versus LAM.
FACING PAGE
Figure 4. Organ distribution of IV-administered PM-NPCs. PKH26-labeled PM-NPC distribution 48 h after injection was inves-
tigated by means of CCD camera. Animals were sacrificed and spinal cords and organs extracted to investigate organ distribution 
of PM-NPCs. (A) The picture shows the high accumulation of the labeled cells at the lesion site and a lower signal in the spleen. 
(B) Comparison of spinal cord fluorescence of PM-NPC-injected mice and placebo-treated animals showed a high and specific fluo-
rescent signal relative to the presence of labeled transplanted cells only in the animals treated with PM-NPCs. Pictures were acquired 
from one PM-NPC treated mouse; however, we observed very similar results in at least three other animals. 
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that MIP-2 expression was diminished by PM-NPCs at 48 h 
and 1 week after lesioning; differently, IL-6, TNF-a, NGF, 
and LIF were reduced at the earlier time, but significantly 
increased at 1 week compared to saline-treated mice. BDNF 
was increased by PM-NPCs in lesioned mice only at 48 h 
(Fig. 9).
Inflammatory Cell Migration to the Lesion Site
The administration of PM-NPCs counteracted the inva-
sion of the lesioned spinal cord by neutrophils and mac-
rophages. Neutrophil infiltration at the site of injury was 
investigated by means of Leder stain throughout the lesion 
site 48 h after lesioning. We chose this time interval since 
the number of neutrophils decreases with time as reported 
previously (5). In Figure 10A it is shown that in the better 
preserved tissue the number of neutrophils is reduced and 
the preventive effect PM-NPCs was quantitatively very 
significant. The effect of the transplanted cells was also 
observed when we monitored the number of ED-1-positive 
cells (macrophages) at the site of the lesion and rostral to 
the lesion (Fig. 10B) 1 week after injury. Both qualitatively 
and quantitatively, the counteracting action of PM-NPCs 
was evident and significant.
DISCUSSION
Considering their characteristic abilities to self-renew 
and differentiate into any cell type in the body, the thera-
peutic promise of stem cells justifies the intense efforts on 
Figure 5. GFAP immunoreactive-positive profiles 28 days after lesioning. PM-NPCs reduce the extent of gliosis in their microen-
vironment in the injured spinal cord. Sections were taken at 1 mm caudal to the lesion site from cords of dead PM-NPC- (A) and 
PM-NPC-treated (B) mice. Quantification of GFAP-positive profiles in a 100-µm radius around PKH26-labeled PM-NPC clusters (C). 
GFAP staining is shown in green and PKH26-labeled PM-NPCs are shown in red. Values represent mean ± SEM. ***p < 0.001 
versus saline.
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Figure 6. PM-NPCs MAP2 transdifferentiation in lesioned cords. GFP-labeled PM-NPCs (A) are clustered at the edges of lesion site 
at 7 days after their IV supplementation to the injured mice, some of them have differentiated into MAP2-positive cells (scale bar: 
100 µm). A magnified detail is represented on the right site of the figure (scale bar: 50 µm). (B) PKH-labeled PM-NPCs (red) are present 
throughout the edges of lesion site at 90 days after their IV administration to SCI mice. Most of them differentiated into MAP2-positive 
cells (green; scale bar: 100 µm). A magnified image is represented on the right site of the figure (scale bar: 50 µm). Most PKH-labeled 
PM-NPCS acquired a neuronal-like shape with dendritic-like processes that intermingle with those of local spinal neurons that survived 
the lesion. Together they form a rich neuropil. All labeled cells have one nucleus. Nuclei are stained in blue (DAPI).
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investigating their application in cell therapy approaches 
(4,5,9,12,15,24,34,37). Recently we reported the isolation 
and characterization of SVZ-derived neuronal precursors 
from mouse cadavers thus named PM-NPCs (23). Their dif-
ferentiation ability leads to a higher proportion of b-tubulin 
III and MAP2-positive cells that can be as high as 45% 
compared to the 10–12% obtained from normal SVZ adult 
NSCs. These cells are also unique in that they produce EPO, 
and their autocrine EPO activation is responsible for their 
higher neural differentiation in vitro (23). In this study, it 
was shown that the treatment of SCI with PM-NPCs attenu-
ates secondary degeneration and enhances significantly the 
amount of tissue sparing and myelin preservation, leading to 
a marked and long-lasting improvement in recovery of motor 
function. This is associated with a progressive and profound 
differentiation of transplanted PM-NPCs into  neuronal-like 
cells with cellular dendritic-like processes positive for 
MAP2, b-tubulin III, and ChAT immunoreactivity.
Tissue Sparing, Reduced Invasion by Inflammatory 
Cells, and Recovery of Function
Transplanted PM-NPCs are located at the edges of the 
injury site and promote a faster and permanent recovery 
of function. This effect must be ascribed to the pres-
ence of the live transplanted PM-NPCs in the cord since 
the transplantation of killed PM-NPCs yields a recov-
ery comparable to that obtained with saline. The long-
lasting effects on the spinal cord were witnessed by the 
hindlimb recovery of function evaluated regularly up 
to 90 days after lesioning and also by the NMR in vivo 
assessment of cord integrity. This is in agreement with 
previous reports that indicated reduced gliosis in the spi-
nal cord after injury when the animals were treated with 
EPO (12,38,40). A marked reduction of macrophage 
and neutrophil invasion of the lesion site was observed 
in PM-NPC-treated animals. This suggests a clear effect 
on the cellular components of the inflammatory reaction 
triggered by SCI; it may be that the reduction of the mac-
rophage number contributes to a decrease in the retraction 
of injured axons through physical cell–cell interactions as 
recently shown (20,21). Neutrophils and hematogenous 
macrophages invade the damaged spinal cord, peaking 
respectively at 12–24 h and 5–7 days after SCI (28,36) 
and releasing proinflammatory cytokines and reactive 
oxygen and nitrogen species (27,35,36). It was shown 
that anti-inflammatory treatments selectively interrupted 
Figure 7. b-Tubulin III expression by PM-NPCs at the edges of the lesion. Pictures representing the edges of the lesion at 90 days 
after IV administration of PKH26-labeled PM-NPCs. The tissue was immunostained for b-tubulin III. Several PM-NPCs are present 
among the surviving neural profiles. Practically all PKH26-labeled cells were positive for b-tubulin III. We show two fields at different 
magnifications (scale bar: 75 or 20 µm), and an enlarged image shows clearly how each labeled cell has one nucleus and bears profiles 
positive for b-tubulin III.
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the early and destructive leukocyte-mediated actions in 
the injured cord, while leaving an opportunity for later 
regenerative interventions and wound healing responses 
(14,16). The reduced cellular component of the inflam-
matory reaction promoted by PM-NPCs may be the basis 
of the observed myelin sparing.
Thus, the enhanced recovery of function might be due 
mainly to a major spinal cord tissue sparing after injury, 
as it was previously reported for agents such as EPO or 
reparixin (12–14). This may contribute to the creation 
of an environment favorable for PM-NPCs survival and 
differentiation.
Homing, Survival, and Differentiation of PM-NPCs
Transplanted PM-NPCs administered by tail vein 
injection of the injured animal are able to reach the lesion 
Figure 8. PM-NPC-transplanted cells differentiate into cholinergic neurons. (A). Some GFP-labeled PM-NPCs clustered at the edges 
of the lesion at 7 days after their IV administration. Several PM-NPCs were positively immunostained for ChAT (red). The pictures 
(scale bar: 100 µm) are enlarged in the right part of the panel (scale bar: 20 µm). (B) Several PKH26-labeled PM-NPCs (red) were 
accumulated at the edges of the lesion 28 days after their IV administration. Most PM-NPCs were positive for ChAT immunostaining 
(green) as shown clearly in the enlarged image on the right side. ChAT stain is dotted and in most cases perinuclear, although some 
positive processes are evident (scale bar: 75 and 20 µm). (C) PKH26-labeled PM-NPCs clustered at the edge of the lesion 60 days after 
their administration. All PM-NPCs were positive for ChAT immunostaining as clearly shown by the two consecutive enlarged images 
(scale bar: 50 µm). The labeling is now diffused throughout the neuron-like cell bodies and in the cellular processes.
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site and remnants of gray matter at its edges, where they 
survive and gradually differentiate in neuron-like cells. 
Analyses performed with both CCD camera and immuno-
histochemistry showed how transplanted PM-NPCs accu-
mulate mostly in the injured region of the spinal cord with 
no signal perceived by the CCD camera in other organs. 
Previous reports had shown that NSCs transplanted into 
injured spinal cord may promote recovery of function, but 
possess a differentiation program generally restricted to 
glial lineages as dictated by the inflammatory– degenerative 
host spinal cord milieu that is not permissive for neural dif-
ferentiation (1,4,6,19,33). The cellular differentiation pro-
cess involving PM-NPCs in the lesioned spinal cord leads 
to a diminution of reactive gliosis in the areas of the cord 
where the transplanted cells are accumulated and to their 
almost total neuronal-like differentiation. This is supported 
by the progressive morphological changes and by the 
expression of neuronal markers such as b-tubulin III and 
MAP2, indicating that unlike other NPCs, PM-NPCs are 
able to differentiate in the lesion environment. We had pre-
viously reported that adult NSCs and ESCs mostly die or 
are phagocytized by macrophages within 10–20 days after 
Figure 9. PM-NPC-transplanted cells affect local expression of cytokines. Expression of cytokine mRNA was evaluated by real 
time RT-PCR. Each group was composed of six mice, and we performed three quantitative RT-PCRs in each experiment. We ran a 
duplicate for each sample and a parallel PCR for the gene of interest and the reference gene GAPDH. Values represent mean ± SEM. 
***p < 0.001, **p < 0.01, *p < 0.05 versus control (CTRL); °°°p < 0.001, °°p < 0.01, °p < 0.05 versus LAM; ###p < 0.001, ##p < 0.01, 
#p < 0.05 versus saline.
Table 1. Percentage of Transplanted PM-NPCs Positive for 
 Neuronal Markers 60 Days After Intravenous Administration
Markers % of PM-NPCs Positively Labeled
b-Tubulin III 94.2 ± 5.1
MAP2 87 ± 4.5
ChAT 78.5 ± 3.7
For the quantification we considered at least four fields per marker. 
Values represent average ± SEM.
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their accumulation at the lesion site in the injured spinal 
cord (4,5,15). Thus, while in those studies we reported an 
acute rapid neuroprotective effect that did not lead to further 
improvement in the recovery at later time once the trans-
planted stem cells had died, here we show an early acute 
effect that gradually keeps improving with time. Owing to 
the small number of surviving transplanted cells compared 
to the massive neural tissue loss after SCI, the potential 
cell replacement suggested by the successful transdiffer-
entiation into a MAP2 and b-tubulin III neuronal pheno-
type cannot be the predominant mechanism. However, the 
finding that almost all PM-NPCs at the injury site acquired 
features of cholinergic neural cells opens the possibility 
that the development of both proneuronal and procholin-
ergic phenotype may be a contributing factor to the mecha-
nisms mediating the neuroprotective effect of these cells. 
Neuroprotection by PM-NPCs might be mediated by com-
plex paracrine actions in agreement with previous studies 
by our group that showed HIF activation in these cells. In 
this sense PM-NPCs produce and secrete EPO that is also 
the key factor for their neuronal differentiation in vitro 
(23). Thus, it is conceivable that PM-NPC preactivation 
of the HIF pathway and erythropoietin paracrine release 
has made these cells able to resist unfavorable conditions 
that take place after the SCI. Literature of the last decade 
has described through several different experimental para-
digms how the supplementation of erythropoietin promotes 
neuroprotection and recovery of function in neurodegen-
erative conditions (26). It should be noted that PM-NPCs 
did not transdifferentiate into GFAP-positive cells nor into 
oligodendrocyte-like cells (data not reported).
CONCLUSIONS
The development of neuroprotective and restorative 
therapies remains a major unfulfilled medical need. In 
this regard, a stem cell-based therapy provides a promis-
ing therapeutic approach for preventing further neuronal 
damage through the attenuation of secondary degenera-
tion and promoting repair and recovery of function after 
SCI. Hypothetically, cell-based therapeutics for SCI could 
affect tissue and/or functional outcomes in a number of 
ways through: (i) differentiation and functional integra-
tion of new cells into spared spinal cord circuitry (e.g., 
forming myelin and/or neurons); (ii) increased sparing of 
host neurons, myelin, and axons, and/or decreased host 
glial scaring; and (iii) increased host-mediated axonal 
regeneration or remyelination. Our study suggests that 
PM-NPCs could affect host hindlimb functional recovery 
after SCI by means of multiple mechanisms just summa-
rized in the three points above. The ability of PM-NPCs to 
survive and differentiate in an unfavorable environment 
such as the site of SCI may derive from their postmortem 
origin and the consequent metabolic and genetic adapta-
tion with activation of hypoxia-induced factor and EPO 
signaling (23,29). The survival of PM-NPCS in the early 
2–3 weeks postinjury is likely crucial for the creation of 
a healthier local milieu that favors neuronal differentia-
tion and regeneration across the lesion of descending and 
ascending pathways (manuscript in preparation). Thus, 
our reported data show that PM-NPCs exert an early neu-
roprotective action not dissimilar from what was seen with 
NSCs and ESCs (4,5), but due to their survival and pos-
sible EPO action, they differentiate into cholinergic neu-
rons and, perhaps, reinforce the migration of host NSCs 
to the site of injury (7,22) that is triggered by SCI (4). 
Thus, it is possible that the early survival of PM-NPCs 
Figure 10. Tissue infiltration by neutrophils and macrophages. 
(A) Neutrophil infiltration was quantitatively assessed at lesion 
epicenter 48 h after lesioning by means of the naphtol AS-D 
chloroacetate (Sigma-Aldrich) technique for esterase. Results 
are expressed as number of neutrophils per HPF. The presence 
of transplanted PM-NPCs greatly reduced the invasion by neu-
trophils. (B) Coronal cryostat section of cord lesion epicenter 
and cord 0.4 mm rostral to the lesion were stained for ED-1, 
and the number of positive cells was quantitatively evaluated 
as described in Materials and Methods. Results are expressed as 
the number of ED-1-positive cells per HPF. For the quantifica-
tion, we considered sections from at least six animals per group. 
Values represent average ± SEM. ***p < 0.001 versus saline.
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is the basis for their neuronal differentiation and the cre-
ation of a more favorable environment that underlies the 
recovery of function.
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